Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4.
Therapy with the antidepressant trazodone has been associated with several cases of idiosyncratic hepatotoxicity. While the mechanism of hepatotoxicity remains unknown, it is possible that reactive metabolites of trazodone play a causative role. Studies were initiated to determine whether trazodone undergoes bioactivation in human liver microsomes to electrophilic intermediates. LC/MS/MS analysis of incubations containing trazodone and NADPH-supplemented microsomes or recombinant P4503A4 in the presence of glutathione revealed the formation of conjugates derived from the addition of the sulfydryl nucleophile to mono-hydroxylated- and hydrated-trazodone metabolites. Product ion spectra suggested that mono-hydroxylation and sulfydryl conjugation occurred on the 3-chlorophenyl-ring, whereas hydration and subsequent sulfydryl conjugation had occurred on the triazolopyridinone ring system. These findings are consistent with bioactivation sequences involving: (1) aromatic hydroxylation of the 3-chlorophenyl-ring in trazodone followed by the two-electron oxidation of this metabolite to a reactive quinone-imine intermediate, which reacts with glutathione in a 1,4-Michael fashion and (2) oxidation of the pyridinone ring to an electrophilic epoxide, ring opening of which, by glutathione or water generates the corresponding hydrated-trazodone-thiol conjugate or the stable diol metabolite, respectively. The pathway involving trazodone bioactivation to the quinone-imine has also been observed with many para-hydroxyanilines including the structurally related antidepressant nefazodone. It is proposed that the quinone-imine and/or the epoxide intermediate(s) may represent a rate-limiting step in the initiation of trazodone-mediated hepatotoxicity.
Pharmacokinetics Dynamics and Metabolism Department, Pfizer Global Research and Development, Eastern Point Road, Groton, MA 06340, USA. amit_kalgutkar@groton.pfizer.com
Amit S
AS
Kalgutkar
Kirk R
KR
Henne
Mary E
ME
Lame
Alfin D N
AD
Vaz
Claire
C
Collin
John R
JR
Soglia
Sabrina X
SX
Zhao
Cornelis E C A
CE
Hop
D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics*; D016227:Benzoquinones / Q000378:metabolism*; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004852:Epoxy Compounds / Q000378:metabolism*; D006801:Humans; D007097:Imines / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins; D021241:Spectrometry, Mass, Electrospray Ionization; D014196:Trazodone / Q000493:pharmacokinetics*
D018687:Antidepressive Agents, Second-Generation; D016227:Benzoquinones; D004852:Epoxy Compounds; D007097:Imines; D011994:Recombinant Proteins; C004532:quinone; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D014196:Trazodone